CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of
investigational ribonucleic acid interference (RNAi) therapeutics, today
announced that Douglas M. Fambrough, Ph.D., president and chief
executive officer, will present a corporate update at the BioCentury 24th
Annual Future Leaders in the Biotech Industry Conference on Friday,
April 7, 2017, at 3:00 p.m. ET. The conference will be
held at the Millennium Broadway Hotel & Conference Center in
New York City.
Management will be available for one-on-one meetings with conference
attendees. To schedule a meeting, contact Paula Schwartz, managing
director, Rx Communications Group, LLC at firstname.lastname@example.org.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative RNAi-based therapeutics for
diseases involving the liver, including rare diseases, chronic liver
diseases, cardiovascular diseases, and viral infectious diseases. The
Company is leveraging its proprietary GalXC™ RNAi technology platform to
build a broad pipeline in these core therapeutic areas, focusing on
target genes where connections between target gene and diseases are well
understood and documented. The Company intends to discover, develop and
commercialize novel therapeutics either on its own or in collaboration
with pharmaceutical partners. For more information, please visit www.dicerna.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170327005985/en/
Rx Communications Group
Alex Van Rees, 973-442-1555 ext. 111
Source: Dicerna Pharmaceuticals, Inc.
News Provided by Acquire Media